Lacki J K, Mackiewicz S H
Kliniki Reumatologii Instytutu Chorób Wewnetrznych Akademii Medycznej, Poznaniu.
Przegl Lek. 1997;54(7-8):543-6.
Ninety-six patients with refractory rheumatoid arthritis were treated with methotrexate for 48 months. We analyzed the effect of low doses of methotrexate (7.5-15 mg weekly) on the activity of the disease and on the progression in damage score. Clinical improvement was observed few weeks after the study was introduced. Following 48 months observation only 32 (33%) remained in the study. Seven of them needed additionally prednisone administration. In 64 (67%) patients the drug was withdrawn: in 18 (19%) due to the side effects, in 24 (25%) due to the lack of effectiveness, in 22 (23%) due to other reasons. Methotrexate did not affect the progression of damage score in our patients. Methotrexate appeared to be usefull drug in the treatment of rheumatoid arthritis, however clinical improvement was observed only during drug administration. After discontinuous of the therapy a flare of the disease was observed.
96例难治性类风湿关节炎患者接受甲氨蝶呤治疗48个月。我们分析了低剂量甲氨蝶呤（每周7.5 - 15毫克）对疾病活动度和损伤评分进展的影响。在研究开始几周后观察到临床改善。经过48个月的观察，只有32例（33%）仍在研究中。其中7例需要额外给予泼尼松。64例（67%）患者停药：18例（19%）因副作用停药，24例（25%）因无效停药，22例（23%）因其他原因停药。甲氨蝶呤对我们患者的损伤评分进展没有影响。甲氨蝶呤似乎是治疗类风湿关节炎的有效药物，然而临床改善仅在用药期间观察到。治疗中断后观察到疾病复发。
